AMRI has completed the acquisition of Cedarburg Pharmaceuticals, Inc. for a total consideration of $41 million, including assumption of certain liabilities.
 
The acquisition of Cedarburg, a contract developer and manufacturer of technically complex API’s for both generic and branded drug products, is part of AMRI’s strategy to expand its presence as a supplier of custom and complex drug development services and product. Customers will now have access to expanded resources, including development of complex API, expanded scale-up capabilities and large-scale manufacturing.